juvenile dermatomyositis: Juvenile dermatomyositis (JDM) is the early-onset form of dermatomyositis (DM, see this term), a systemic, autoimmune inflammatory muscle disorder, characterized by proximal muscle weakness, evocative skin lesion, and systemic manifestations.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersNone 0 out of 7 registries used, show all original rules. |
0 |
4. Check minimum number of eventsNone |
0 |
5. Include endpoints |
517 |
6. Filter based on genotype QC (FinnGen only) |
517 |
Control definitions (FinnGen only)
- Control exclude
- RHEUMA_ENDPOINTS
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Dermatopolymyositis (FG)
based on the number of shared cases.
Similar with more cases:
- Dermatopolymyositis
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Finngen Rheumatological endpoints
- Autoimmune diseases
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3476 | 2143 | 1288 |
| Only index persons | 2514 | 1586 | 928 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.06 | 0.04 |
| Only index persons | 0.05 | 0.06 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 59.02 | 59.14 | 58.69 |
| Only index persons | 55.63 | 55.68 | 55.54 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 517 | 320 | 197 |
| Unadjusted period prevalence (%) | 0.10 | 0.11 | 0.09 |
| Median age at first event (years) | 55.30 | 53.71 | 57.88 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 477
- Matched controls
- 4770
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M33.2
ICD-10 Finland
Polymyositis
+∞
276.9
238
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
101.4
244.1
259
55
M33.9
ICD-10 Finland
Dermatopolymyositis, unspecified
+∞
190.8
170
*
M33.1
ICD-10 Finland
Other dermatomyositis
+∞
171.5
154
*
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
80.6
170.6
188
38
P01BA02
ATC
hydroxychloroquine; oral
59.2
132.2
154
38
L04AX01
ATC
azathioprine; systemic
37.8
115.1
148
56
M60.9
ICD-10 Finland
Myositis, unspecified
446.9
107.9
104
*
H02AB06
ATC
prednisolone; systemic
9.7
104.7
380
1375
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
7.5
89.3
312
962
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
44.7
76.5
94
26
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
+∞
71.7
67
*
G72.9
ICD-10 Finland
Myopathy, unspecified
112.7
71.3
76
8
M05BA04
ATC
alendronic acid; oral
11.7
66.1
131
149
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
13.2
65.1
121
120
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
129.5
63.7
67
6
NXL00
NOMESCO Finland
Biopsy of muscle
177.6
60.5
62
*
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
161.3
55.2
57
*
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
27.1
50.6
70
30
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
278.4
50.1
50
*
M60.8
ICD-10 Finland
Other myositis
504.6
47.1
46
*
H02AB07
ATC
prednisone; oral
6.1
46.8
146
322
L88
ICPC
Rheumatoid/seropositive arthritis
111.4
46.8
50
5
L04AA06
ATC
mycophenolic acid; systemic
28.5
42.7
58
23
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.8
42.0
275
1248
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
6.9
41.3
112
202
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
82.3
40.7
45
6
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
149.1
39.4
41
*
J99.1*M33.2
ICD-10 Finland
Respiratory disorders in polymyositis
+∞
35.9
34
*
M13.9
ICD-10 Finland
Arthritis, unspecified
24.1
33.8
48
22
L04AD01
ATC
ciclosporin; systemic
24.7
33.4
47
21
M17.1
ICD-10 Finland
Other primary gonarthrosis
9.0
32.0
70
89
M35.1
ICD-10 Finland
Other overlap syndromes
+∞
29.5
28
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
8.2
29.3
68
95
L04AA01
ATC
[U] ciclosporin; systemic
30.7
28.0
37
13
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
9.8
25.8
53
60
NGB20
NOMESCO Finland
Primary total prosthetic replacement of knee joint without patellar part
+∞
25.2
24
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.0
24.7
185
828
M05BA07
ATC
risedronic acid; oral
9.8
23.4
48
54
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
+∞
23.1
22
*
J99.1
ICD-10 Finland
Respiratory disorders in other diffuse connective tissue disorders
+∞
22.0
21
*
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
120.5
21.8
23
*
L99
ICPC
Musculoskeletal disease other
22.0
21.5
31
15
A02BC02
ATC
pantoprazole; systemic
2.6
21.5
332
2220
7104A
ICD-9 Finland
Diffuse diseases of connective tissue, Polymyositis
+∞
21.0
20
*
M33.0
ICD-10 Finland
Juvenile dermatomyositis
219.1
20.7
21
*
M35.3
ICD-10 Finland
Polymyalgia rheumatica
19.4
20.7
31
17
R50.9
ICD-10 Finland
Fever, unspecified
3.7
20.6
98
308
C03CA01
ATC
furosemide; systemic
2.8
20.4
169
783
L28
ICPC
Limited function/disability (L)
3.7
20.0
97
310
J99.1*M33.9
ICD-10 Finland
Respiratory disorders in dermatopolymyositis
+∞
19.9
19
*
71610
ICD-8 Finland
Polymyositis and dermatomyositis, Polymyositis
+∞
19.9
19
*
NJ2MA
NOMESCO Finland
Measurement of mechanical axis of lower leg with X-ray
48.1
19.4
23
5
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
12.1
19.3
35
31
R4110
NOMESCO Finland
Physiotherapy
2.8
19.1
154
701
L04AA13
ATC
leflunomide; oral
197.4
18.7
19
*
ZX120
NOMESCO Finland
Intravenous
4.1
18.6
77
213
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
45.9
18.4
22
5
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
13.2
17.9
31
25
L30.9
ICD-10 Finland
Dermatitis, unspecified
3.1
17.8
108
406
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
9.2
17.8
37
43
XX9XE
NOMESCO Finland
Other ultrasound examination
186.6
17.6
18
*
TPH04
NOMESCO Finland
Cathetrisation of vein
2.9
17.6
125
521
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.7
17.4
145
667
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.3
17.0
93
323
TGC00
NOMESCO Finland
Bronchial lavation
10.3
16.9
33
34
N03AX16
ATC
pregabalin; oral
2.8
16.7
129
564
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
4.7
16.2
56
130
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
20.1
15.7
23
12
R13
ICD-10 Finland
Dysphagia
4.5
15.6
57
140
JN4BD
NOMESCO Finland
Extensive body CT
3.5
15.6
79
259
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.6
15.4
73
226
A07EC01
ATC
sulfasalazine; oral, rectal
7.9
15.0
34
46
R06.0
ICD-10 Finland
Dyspnoea
2.5
14.8
139
675
71600
ICD-8 Finland
Polymyositis and dermatomyositis, Dermatomyositis
+∞
14.7
14
*
NF1AA
NOMESCO Finland
Hip X-ray examination
6.7
14.6
37
59
G72.8
ICD-10 Finland
Other specified myopathies
11.9
14.4
26
23
XG410
NOMESCO Finland
Flow-volume spirometry
5.9
14.3
40
73
UGC12
NOMESCO Finland
Flexible bronchoscopy
3.9
14.0
60
171
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
18.2
13.9
21
12
M17.0
ICD-10 Finland
Primary gonarthrosis, bilateral
5.9
13.9
39
71
H26.3
ICD-10 Finland
Drug-induced cataract
55.0
13.9
16
*
XPX04
NOMESCO Finland
Angioscopy
77.4
13.6
15
*
M33
ICD-10 Finland
Dermatopolymyositis
+∞
13.6
13
*
NJ3DG
NOMESCO Finland
Very extensive MRI examination of extremities with high intensity magnet
+∞
13.6
13
*
7103B
ICD-9 Finland
Diffuse diseases of connective tissue, Dermatomyositis[DERMATOMYOSITIS ADULTORUM]
+∞
13.6
13
*
R4120
NOMESCO Finland
Occupational therapy
4.4
13.2
49
122
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.6
13.0
103
450
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.4
13.0
66
216
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.5
12.9
117
551
M06.0
ICD-10 Finland
Seronegative rheumatoid arthritis
51.5
12.9
15
*
1XC02
NOMESCO Finland
NA
51.5
12.9
15
*
M79.0
ICD-10 Finland
Rheumatism, unspecified
7.8
12.9
29
39
L19
ICPC
Muscle symptom/complaint NOS
7.6
12.7
29
40
G71.9
ICD-10 Finland
Primary disorder of muscle, unspecified
+∞
12.5
12
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.9
12.4
52
145
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.8
12.4
54
156
E0000UV
ATC
NA
2.1
12.3
197
1207
C08CA05
ATC
nifedipine; systemic
4.1
12.3
49
131
B01AB05
ATC
enoxaparin; parenteral
2.3
12.3
132
678
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
27.5
12.1
16
6
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.1
12.1
182
1083
XA402
NOMESCO Finland
ENMG
6.7
12.1
30
47
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.2
12.0
141
750
Z01.8
ICD-10 Finland
Other specified special examinations
2.4
11.7
116
569
318
Kela drug reimbursment
Teriparatide
66.6
11.7
13
*
H05AA02
ATC
teriparatide; parenteral
66.6
11.7
13
*
TND11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in joint, wrist or hand
66.6
11.7
13
*
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
3.2
11.5
64
222
S18
ICPC
Laceration/cut
2.0
11.5
193
1193
N02AX02
ATC
tramadol; systemic, rectal
2.0
11.5
190
1167
A07AA02
ATC
nystatin; oral
3.9
11.5
48
134
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.4
11.2
55
175
M25.5
ICD-10 Finland
Pain in joint
2.2
11.1
128
675
D07AC01
ATC
betamethasone; topical
2.0
10.8
171
1029
D07AB08
ATC
desonide; topical
2.9
10.8
67
252
NH3DA
NOMESCO Finland
Bilateral foot X-ray examination
18.3
10.8
16
9
5BA08
NOMESCO Finland
NA
61.4
10.7
12
*
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.1
10.6
61
218
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.1
10.6
144
812
J01FF01
ATC
clindamycin; systemic
2.2
10.6
130
702
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
3.7
10.5
46
134
M81.4
ICD-10 Finland
Drug-induced osteoporosis
112.3
10.5
11
*
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
112.3
10.5
11
*
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
3.8
10.4
44
124
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
3.9
10.4
42
114
A02BC01
ATC
omeprazole; systemic
2.1
10.3
139
780
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
5.6
10.3
29
54
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.6
10.2
79
338
J05AB01
ATC
aciclovir; systemic
2.2
10.2
111
567
A02BC05
ATC
esomeprazole; systemic
1.9
10.1
194
1251
M79.1
ICD-10 Finland
Myalgia
2.8
10.0
69
276
M05BX04
ATC
denosumab; parenteral
4.5
10.0
35
83
Z50.1
ICD-10 Finland
Other physical therapy
4.2
10.0
37
93
J01DB01
ATC
cefalexin; oral
2.0
9.9
373
3044
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
4.8
9.9
32
70
N06AA09
ATC
amitriptyline; systemic
3.1
9.8
55
192
M16.0
ICD-10 Finland
Primary coxarthrosis, bilateral
13.7
9.7
16
12
M16.1
ICD-10 Finland
Other primary coxarthrosis
8.1
9.7
21
27
NFB30
NOMESCO Finland
Primary total prosthetic replacement of hip joint not using cement
56.1
9.7
11
*
NG4AA
NOMESCO Finland
Lower leg X-ray examination
6.6
9.7
24
38
NE1AA
NOMESCO Finland
Pelvis X-ray examination
4.8
9.6
31
68
WZA10
NOMESCO Finland
Long statement of health and health related matters
15.4
9.6
15
10
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.2
9.5
49
163
A28
ICPC
Limited function/disability NOS
2.5
9.5
75
326
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.9
9.5
200
1326
M62.9
ICD-10 Finland
Disorder of muscle, unspecified
30.7
9.4
12
*
M80.4
ICD-10 Finland
Drug-induced osteoporosis with pathological fracture
+∞
9.4
9
*
212
Kela drug reimbursment
Gout
+∞
9.4
9
*
QBA99
NOMESCO Finland
Other local destruction of skin of trunk
22.2
9.4
13
6
H02AB04
ATC
methylprednisolone; systemic
2.5
9.4
79
353
XQ848
NOMESCO Finland
Dermatological photography
6.7
9.4
23
36
M48.0
ICD-10 Finland
Spinal stenosis
2.9
9.2
58
220
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
5.2
9.1
27
54
L93.0
ICD-10 Finland
Discoid lupus erythematosus
37.4
9.0
11
*
EBA10
NOMESCO Finland
Surgical removal of tooth
2.8
9.0
60
235
N02AA05
ATC
oxycodone; systemic
2.5
8.9
71
308
RF420
NOMESCO Finland
NA
11.0
8.8
16
15
UJF32
NOMESCO Finland
Coloscopy
2.0
8.6
125
715
TNG10
NOMESCO Finland
Puncture of knee
28.1
8.5
11
*
NH3EA
NOMESCO Finland
Feet X-ray examination with load
13.1
8.4
14
11
R52.2
ICD-10 Finland
Other chronic pain
5.4
8.4
24
46
D07AC13
ATC
mometasone; topical
1.9
8.4
140
846
N28
ICPC
Limited function/disability (N)
8.8
8.4
17
20
NGB40
NOMESCO Finland
Primary total prosthetic replacement of knee joint with patellar part - sliding prosthesis
+∞
8.4
8
*
7140A
ICD-9 Finland
Rheumatoid arthritis and other inflammatory polyarthropathies, Rheumatoid arthritis[ARTHRITIS RHEUMATOIDES SEROPOSITIVA]
+∞
8.4
8
*
UJF30
NOMESCO Finland
Ileoscopy through colon
2.9
8.3
52
196
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.1
8.3
44
150
C07AB07
ATC
bisoprolol; oral
1.8
8.2
219
1545
M01AH01
ATC
celecoxib; oral (coxibs)
2.3
8.2
77
363
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.3
8.2
81
391
SPAT1229
SPAT
Assessment of need for aid
3.1
8.1
44
152
N03AX12
ATC
gabapentin; oral
2.4
8.1
71
324
SPAT1216
SPAT
Assessment of functional ability
2.4
7.9
70
319
RF410
NOMESCO Finland
NA
13.3
7.9
13
10
R53
ICD-10 Finland
Malaise and fatigue
2.1
7.9
100
542
WX002
NOMESCO Finland
Sedation and analgesia
2.2
7.8
88
453
NB1AE
NOMESCO Finland
Shoulder ultrasound examination
11.0
7.8
14
13
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
5.2
7.8
23
46
M01AH02
ATC
rofecoxib; oral
2.5
7.7
62
271
WX320
NOMESCO Finland
Spinalanesthesy
2.2
7.7
81
404
TNB11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in shoulder joint
45.7
7.7
9
*
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
6.3
7.6
19
31
M05BA01
ATC
etidronic acid; systemic
25.5
7.6
10
*
WX408
NOMESCO Finland
General anesthesy, balanced
1.9
7.6
126
756
A01AB09
ATC
miconazole; local oral
2.7
7.6
52
209
J01DA01
ATC
[U] cefalexin; systemic
1.7
7.5
289
2254
N02AJ06
ATC
codeine and paracetamol; systemic
1.8
7.5
149
950
R1250
NOMESCO Finland
Evaluation of functional capability
6.6
7.5
18
28
M79.6
ICD-10 Finland
Pain in limb
1.8
7.5
149
951
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
81.3
7.4
8
*
M17.3
ICD-10 Finland
Other post-traumatic gonarthrosis
81.3
7.4
8
*
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
81.3
7.4
8
*
M05.9
ICD-10 Finland
Seropositive rheumatoid arthritis, unspecified
81.3
7.4
8
*
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.2
7.4
77
383
NH3BA
NOMESCO Finland
Foot and toes extensive X-ray examination
5.1
7.4
22
45
G73.7*M35.0
ICD-10 Finland
Myopathy in sicca syndrome [Sjögren]
+∞
7.3
7
*
G71.08
ICD-10 Finland
Other muscular dystrophy
+∞
7.3
7
*
M31.1
ICD-10 Finland
Thrombotic microangiopathy
+∞
7.3
7
*
6BA02
NOMESCO Finland
NA
+∞
7.3
7
*
M04AA01
ATC
allopurinol; systemic
2.6
7.3
53
219
M05BB03
ATC
alendronic acid and colecalciferol; oral
5.6
7.3
20
37
E000001
ATC
NA
2.0
7.2
102
575
M13.0
ICD-10 Finland
Polyarthritis, unspecified
30.5
7.2
9
*
NG1DA
NOMESCO Finland
X-ray of knees
20.4
7.2
10
5
N99
ICPC
Neurological disease other
9.0
7.1
14
16
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
3.4
7.1
33
103
M01AX01
ATC
nabumetone; oral
4.4
7.0
24
57
R4190
NOMESCO Finland
Nutritional therapy
4.2
7.0
25
62
H05BA01
ATC
calcitonin (salmon synthetic); nasal, parenteral
4.2
7.0
25
62
GD1AD
NOMESCO Finland
Thorax CT examination
4.0
7.0
26
67
SPAT1231
SPAT
Assessment of adjustments needed in living environment
6.0
7.0
18
31
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.2
7.0
73
361
A02BC03
ATC
lansoprazole; oral
1.8
6.9
143
923
D07AB02
ATC
hydrocortisone butyrate; topical
1.8
6.9
131
820
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.3
6.9
62
289
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.7
6.8
45
177
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
2.0
6.8
99
562
SPAT1253
SPAT
Initiation, adjustment, discontinuation or repetition of medication
1.8
6.8
138
881
XG466
NOMESCO Finland
Sleep oxymetry
4.2
6.8
24
59
QCA99
NOMESCO Finland
Other local destruction of skin of upper limb
40.6
6.8
8
*
XX6XT
NOMESCO Finland
Other intravascular therapy with radiological guidance
40.6
6.8
8
*
NA1EA
NOMESCO Finland
Cervical spine X-ray examination with flexion
22.9
6.7
9
*
WZC10
NOMESCO Finland
Extensive specialist consultion with written report
3.8
6.7
27
75
WZB00
NOMESCO Finland
Telephone receipt or other advice
1.8
6.7
122
752
M79.7
ICD-10 Finland
Fibromyalgia
6.0
6.7
17
29
L29
ICPC
Musculoskeletal sympt/complt other
2.8
6.7
42
159
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
2.5
6.6
49
205
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
4.5
6.6
22
51
J02AC01
ATC
fluconazole; systemic
1.7
6.6
178
1237
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
4.9
6.6
20
42
RF120
NOMESCO Finland
NA
10.2
6.6
12
12
F45.4
ICD-10 Finland
Persistent somatoform pain disorder
10.2
6.6
12
12
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.3
6.6
59
272
RF210
NOMESCO Finland
NA
5.5
6.5
18
34
J01MA12
ATC
levofloxacin; systemic
2.0
6.5
86
471
M05BA06
ATC
ibandronic acid; systemic
6.3
6.5
16
26
SPAT1262
SPAT
Handing over of treatment supplies
2.0
6.5
84
455
C08CA01
ATC
amlodipine; oral
1.7
6.5
161
1092
SPAT1153
SPAT
Removal of sutures
1.8
6.4
132
844
QC6S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in hand
70.7
6.4
7
*
M60.0
ICD-10 Finland
Infective myositis
70.7
6.4
7
*
71239
ICD-8 Finland
Rheumatoid arthritis and allied conditions, Arthritis rheumatoides NUD
70.7
6.4
7
*
L18
ICPC
Muscle pain
5.0
6.4
19
39
ZXA00
NOMESCO Finland
Right side
1.8
6.4
115
703
I50.9
ICD-10 Finland
Heart failure, unspecified
2.2
6.4
61
292
SAA03
NOMESCO Finland
Extended examination of mouth
1.7
6.4
159
1079
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
11.2
6.3
11
10
NG2AA
NOMESCO Finland
Patella X-ray examination
18.3
6.3
9
5
ZX140
NOMESCO Finland
Intra articular
+∞
6.3
6
*
M34.1
ICD-10 Finland
CR(E)ST syndrome
+∞
6.3
6
*
7151F
ICD-9 Finland
Osteo-arthrosis and allied disorders, Osteo-arthrosis, localised, primary[OSTEOARTHROSIS PRIMARIA, POLVI]
+∞
6.3
6
*
M32.0
ICD-10 Finland
Drug-induced systemic lupus erythematosus
+∞
6.3
6
*
QDA99
NOMESCO Finland
Other local destruction of skin of lower limb
27.0
6.2
8
*
ZXM10
NOMESCO Finland
Intraoperative use of conventional X-ray imaging
3.6
6.2
26
75
J05AB11
ATC
valaciclovir; oral
2.2
6.2
64
317
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
2.8
6.2
37
138
ZXA05
NOMESCO Finland
Left side
1.8
6.1
110
673
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.1
6.1
72
378
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
12.7
6.1
10
8
NK1XE
NOMESCO Finland
Other ultrasound examinnation of muscle or tendon
12.7
6.1
10
8
FM1DG
NOMESCO Finland
Very extensive MRI examination of heart with high intesity magnet
8.8
6.1
12
14
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
2.6
6.1
42
168
M80.0
ICD-10 Finland
Postmenopausal osteoporosis with pathological fracture
10.2
6.1
11
11
H04.10
ICD-10 Finland
Dry eye syndrome
2.4
6.0
49
217
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
155
113
19.16
175.80
6.0
2.1
556.2
699.2
ug/l
0.12
150
105
380
1118
10.05
142.48
12.1
2.0
240.3
328.3
u/l
0.49
375
1063
104
60
21.45
130.96
1.7
1.1
50.0
—
u/ml
—
10
0
107
90
14.73
109.88
2.2
1.3
—
—
—
0
0
110
8
174.07
107.92
1.4
1.0
—
—
—
0
0
94
79
14.32
96.17
1.6
1.1
12.4
5.7
u/ml
—
25
8
93
79
14.13
94.48
1.6
1.1
1.8
2.9
u/ml
—
13
7
78
67
13.53
78.30
1.5
1.5
300.1
0.2
iu/ml
0.47
11
11
369
1749
4.88
62.52
16.8
4.7
59.4
56.7
%
4.05
363
1631
372
1777
4.90
62.30
17.2
4.8
26.0
28.2
%
3.79
366
1651
44
20
23.95
60.27
1.4
1.1
—
—
—
0
0
44
20
23.95
60.27
1.4
1.1
—
—
—
0
0
44
20
23.95
60.27
1.4
1.1
—
—
—
0
0
44
20
23.95
60.27
1.4
1.1
—
—
—
0
0
44
20
23.95
60.27
1.4
1.1
—
—
—
0
0
405
2184
4.94
54.59
19.5
8.7
4.2
4.0
e9/l
0.91
389
1888
117
331
4.28
37.77
1.8
2.2
352.2
396.3
nmol/l
0.59
110
310
428
2830
3.98
33.75
12.9
3.1
15.0
11.6
mm/h
5.03
417
2565
318
1772
3.06
33.50
10.5
5.5
1.2
1.2
mmol/l
0.20
303
1587
333
1932
3.03
32.07
12.1
6.3
1.2
1.2
mmol/l
0.18
291
1620
25
15
17.46
29.96
2.2
2.0
—
—
—
0
0
285
1569
2.82
29.43
3.2
2.2
76.9
78.5
nmol/l
0.43
269
1384
26
18
15.16
28.97
2.2
1.9
18.6
11.4
%
—
14
9
27
21
13.51
28.20
1.6
1.1
2.2
—
u/ml
—
5
0
27
24
11.81
25.98
1.6
1.1
103.5
—
u/ml
—
8
0
58
125
5.10
25.90
3.0
2.7
3.1
3.0
g/l
0.40
51
101
57
123
5.08
25.41
3.0
2.7
10.3
10.6
g/l
0.12
51
108
42
68
6.63
25.29
10.0
6.3
519.6
213.4
iu/ml
—
9
13
59
132
4.92
25.21
3.0
2.7
3.5
3.5
g/l
0.06
50
100
59
132
4.92
25.21
3.0
2.7
7.2
6.9
g/l
0.62
52
102
59
132
4.92
25.21
3.0
2.7
—
—
—
0
0
305
1858
2.56
23.92
5.4
3.3
0.0
0.0
estimate
0.00
61
338
305
1888
2.50
22.66
5.5
3.4
0.0
0.0
estimate
0.80
65
332
130
536
2.90
22.34
1.4
1.2
61.7
17.9
iu/ml
1.59
42
159
56
134
4.57
22.00
3.2
2.9
—
—
—
0
0
49
105
5.05
21.97
3.3
2.7
0.0
0.1
g/l
0.50
49
98
140
607
2.79
21.85
2.3
1.9
—
—
—
0
0
301
1877
2.44
21.63
7.2
4.8
0.0
0.0
estimate
0.50
64
339
25
26
10.05
21.60
2.4
1.6
—
—
—
0
0
209
1115
2.47
21.18
4.6
2.8
1091.4
1251.7
ng/l
0.34
192
938
47
101
5.02
20.99
3.4
2.7
0.0
0.0
g/l
0.00
47
94
47
101
5.02
20.99
3.4
2.7
0.0
0.0
g/l
0.00
47
94
140
621
2.72
20.79
6.5
3.1
0.8
0.8
mmol/l
0.86
132
586
27
33
8.58
20.68
1.5
1.0
—
—
—
0
0
273
1673
2.34
19.83
7.3
4.4
34.0
35.7
g/l
4.76
264
1552
17
11
15.95
19.43
1.4
1.0
12.2
83.8
%
—
9
6
42
89
5.05
19.04
1.8
1.6
—
—
—
0
0
114
474
2.80
19.03
2.9
2.3
23.1
23.9
%
0.20
99
409
22
24
9.53
18.32
1.7
1.1
4675.6
16086.8
e6/l
0.72
16
17
83
296
3.15
18.20
4.4
3.1
186.0
199.8
ng/l
0.13
75
280
43
97
4.74
18.11
1.3
1.2
—
—
—
0
0
73
244
3.32
17.80
2.4
2.5
11.3
15.8
au/ml
—
5
13
41
92
4.75
17.37
1.9
1.6
—
—
—
0
0
34
65
5.53
17.25
1.5
1.4
—
—
—
0
0
191
1059
2.27
16.95
4.4
2.8
0.3
0.6
e6/l
2.07
154
787
32
59
5.72
16.87
1.4
1.4
96.3
112.3
u/ml
—
6
7
33
64
5.44
16.49
1.2
1.3
—
—
—
0
0
113
501
2.61
16.44
1.3
1.2
33.8
3.5
u/ml
1.01
33
191
31
60
5.43
15.51
1.2
1.2
299.6
226.0
u/ml
0.53
21
31
32
64
5.26
15.45
1.8
1.4
—
—
—
0
0
19
22
8.93
15.10
2.1
2.3
924.7
521.1
e6/l
—
7
9
162
876
2.24
14.97
4.0
2.5
2731.6
10265.1
umol/l
1.77
149
748
213
1283
2.12
14.96
6.1
3.0
48.6
33.0
u/l
2.54
203
1212
128
627
2.38
14.91
3.5
2.5
0.7
1.0
e6/l
1.60
85
338
161
871
2.23
14.84
2.7
1.9
3.3
3.1
mg/l
0.34
144
723
99
434
2.58
14.63
2.2
1.8
—
—
—
0
0
20
26
7.96
14.51
1.2
1.2
61.3
110.0
titre
—
8
5
104
473
2.50
14.20
8.7
4.9
1.0
1.0
mmol/l
0.19
99
438
29
58
5.24
14.00
5.1
2.9
62.2
58.2
%
0.88
29
58
32
70
4.81
13.95
1.8
1.7
—
—
—
0
0
301
2096
2.04
13.92
8.7
6.3
10.1
11.2
umol/l
1.78
290
1974
28
56
5.23
13.51
4.8
2.8
4.5
4.2
e9/l
0.32
28
56
158
883
2.14
13.19
1.3
1.2
0.9
1.9
u/ml
0.93
33
222
95
431
2.48
12.97
2.2
1.8
—
—
—
0
0
39
106
3.90
12.89
5.7
5.3
34.2
30.6
mg/l
0.15
32
93
24
46
5.42
12.12
1.4
1.5
—
—
—
0
0
38
106
3.79
12.12
5.9
5.3
45.1
49.8
mg/l
0.13
32
92
25
51
5.10
11.80
1.0
1.2
3.0
7.0
u/ml
0.32
11
13
25
51
5.10
11.80
1.4
1.5
—
—
—
0
0
67
275
2.65
11.19
2.1
1.5
—
—
—
0
0
89
418
2.36
11.18
13.5
7.0
10.5
12.5
kpa
3.97
79
403
89
418
2.36
11.18
13.6
7.0
5.2
5.0
kpa
0.59
79
401
70
296
2.58
11.01
2.9
2.4
18.4
6.8
ug/l
2.35
61
258
341
2593
1.93
11.01
6.4
4.0
15.4
2600.4
e6/l
—
5
42
133
741
2.07
10.93
6.1
3.9
235.1
289.6
ng/l
0.21
115
575
25
55
4.73
10.82
2.0
1.5
—
—
—
0
0
24
51
4.89
10.82
2.0
1.5
—
—
—
0
0
13
14
9.50
10.80
1.0
1.2
—
—
—
0
0
20
36
5.74
10.77
1.1
1.1
—
—
—
0
0
124
680
2.08
10.60
1.8
1.7
1125.6
1225.0
nmol/l
0.61
101
510
87
416
2.31
10.45
13.8
7.0
1.5
1.0
mmol/l
0.38
66
326
236
1618
1.84
10.35
3.5
2.6
194.5
126.5
ug/l
1.94
224
1485
13
15
8.86
10.27
2.0
1.3
—
—
—
0
0
16
24
6.85
10.23
1.1
1.2
—
—
—
0
0
204
1357
1.83
9.71
3.6
3.7
2.3
2.4
mmol/l
2.46
188
1199
305
2290
1.81
9.67
9.0
4.4
6.6
6.7
mmol/l
0.56
293
2154
21
45
4.82
9.37
1.2
1.4
—
—
—
0
0
21
46
4.72
9.14
1.5
1.2
—
—
—
0
0
149
918
1.88
8.93
1.7
1.5
19.7
20.8
nmol/l
0.47
132
765
109
611
1.99
8.63
3.9
2.6
3.4
2.4
e6/l
0.63
68
326
21
49
4.42
8.48
1.7
1.6
—
—
—
0
0
20
45
4.58
8.43
1.7
1.7
—
—
—
0
0
22
55
4.13
8.15
1.0
1.2
2.4
4.8
u/ml
—
8
24
133
811
1.86
8.15
2.2
1.6
1.2
1.2
mg/l
0.13
100
616
213
1501
1.71
7.92
5.2
3.3
95.6
65.5
ng/l
0.47
180
1019
46
189
2.57
7.65
18.4
9.0
24.6
24.4
mmol/l
0.16
41
181
11
6
18.69
7.63
1.6
2.0
—
—
—
0
0
181
1240
1.71
7.34
2.7
2.3
54.4
57.1
u/l
0.50
168
1129
153
1001
1.75
7.32
6.6
3.4
0.0
0.0
estimate
0.80
64
333
83
451
2.00
7.10
3.4
2.8
6.7
8.9
umol/l
0.85
70
392
18
43
4.30
7.06
2.2
1.7
—
—
—
0
0
15
31
4.95
6.97
1.1
1.0
—
—
—
0
0
11
8
14.01
6.91
1.9
1.4
8.4
9.0
ug/l
—
11
8
11
17
6.59
6.80
1.7
3.6
1187.1
1198.9
u/ml
0.01
11
17
216
1580
1.63
6.66
2.2
1.9
95.0
94.7
pmol/l
0.03
120
777
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
28
95
3.06
6.64
5.0
2.5
0.4
0.4
u/ml
0.05
19
56
202
1456
1.64
6.59
6.0
3.6
—
—
—
0
0
10
15
6.78
6.33
1.0
1.0
—
—
—
0
0
31
116
2.78
6.20
1.4
1.1
—
—
—
0
0
27
94
2.98
6.14
1.2
1.5
—
—
—
0
0
16
39
4.20
6.13
1.5
1.6
—
—
—
0
0
16
39
4.20
6.13
1.5
1.6
—
—
—
0
0
16
39
4.20
6.13
1.5
1.6
—
—
—
0
0
450
4011
1.94
6.09
32.1
12.2
19.6
25.1
mg/l
4.36
417
3045
13
27
4.91
6.00
2.2
1.7
2.7
2.5
mg/l
0.23
13
27
9
6
15.23
5.92
1.1
1.7
—
—
—
0
0
77
434
1.91
5.90
28.5
22.6
1.9
1.2
inr
—
7
51
24
80
3.10
5.88
2.5
1.4
—
—
—
0
0
30
115
2.71
5.75
1.3
1.1
—
—
—
0
0
12
25
4.89
5.52
1.0
1.1
—
—
—
0
0
13
30
4.42
5.32
1.5
3.6
—
—
—
0
0
9
9
10.15
5.04
1.0
1.0
90.7
297.4
iu/ml
—
9
9
32
137
2.42
4.93
2.7
1.9
—
—
—
0
0
11
24
4.66
4.80
1.0
1.1
0.1
0.3
nmol/l
—
5
5
43
212
2.12
4.78
1.6
1.4
—
—
—
0
0
62
350
1.88
4.73
18.3
7.6
120.7
121.2
g/l
0.07
57
340
218
1698
1.49
4.63
5.0
3.7
—
—
—
0
0
44
222
2.07
4.61
2.0
1.7
—
—
—
0
0
118
807
1.60
4.53
6.9
3.4
1.0
1.0
kg/l
0.48
19
113
63
366
1.82
4.39
2.3
2.3
367.4
37.2
u/l
0.49
54
307
8
9
9.01
4.29
1.3
2.0
—
—
—
0
0
39
200
2.03
3.94
1.4
1.3
—
—
—
0
0
111
773
1.56
3.90
2.4
3.0
2.5
2.5
mmol/l
0.77
94
689
42
223
1.96
3.86
11.7
6.5
24.9
24.3
mmol/l
0.40
37
211
16
55
2.97
3.77
1.1
1.1
—
—
—
0
0
59
354
1.75
3.71
6.2
3.4
2.1
1.8
mmol/l
0.30
51
283
22
91
2.48
3.69
1.4
1.3
—
—
—
0
0
22
91
2.48
3.69
1.4
1.3
—
—
—
0
0
8
12
6.75
3.68
2.3
1.2
35.8
89.0
u/l
—
8
12
8
12
6.75
3.68
1.1
1.0
—
—
—
0
0
27
126
2.21
3.48
2.5
1.7
—
—
—
0
0
308
2648
1.40
3.46
4.1
2.9
55.4
47.5
u/l
0.89
295
2455
114
821
1.50
3.41
1.6
1.7
65421004.9
11027631.6
pmol/l
0.38
107
662
10
27
3.76
3.37
1.5
1.7
—
—
—
0
0
9
19
4.80
3.25
1.0
1.1
—
—
—
0
0
13
44
3.00
3.15
1.0
1.1
—
—
—
0
0
13
45
2.94
3.04
3.4
2.2
90.5
89.3
%
0.51
13
45
5
5
10.08
2.98
3.8
1.4
—
—
—
0
0
8
17
4.76
2.93
1.5
1.2
—
—
—
0
0
10
31
3.27
2.78
1.0
1.1
304.0
283.8
mg/l
—
10
25
25
125
2.05
2.75
1.6
1.1
—
—
—
0
0
7
14
5.05
2.73
1.1
1.0
—
—
—
0
0
114
856
1.43
2.72
2.8
2.2
—
—
—
0
0
5
7
7.20
2.55
2.0
1.9
—
—
—
0
0
10
33
3.07
2.54
1.2
1.0
—
—
—
0
0
10
33
3.07
2.54
1.3
1.2
—
—
—
0
0
10
33
3.07
2.54
1.2
1.2
—
—
—
0
0
8
22
3.68
2.37
1.3
1.1
—
—
—
0
0
8
22
3.68
2.37
1.3
1.1
—
—
—
0
0
7
17
4.16
2.36
1.7
1.8
—
—
—
0
0
7
17
4.16
2.36
1.7
1.8
—
—
—
0
0
7
17
4.16
2.36
1.7
1.8
—
—
—
0
0
19
91
2.13
2.35
2.1
1.5
—
—
—
0
0
23
119
1.98
2.34
1.3
1.5
295.1
282.1
ug/g
0.11
15
73
8
23
3.52
2.28
1.6
1.6
—
—
—
0
0
8
23
3.52
2.28
1.6
1.6
—
—
—
0
0
8
23
3.52
2.28
1.6
1.6
—
—
—
0
0
8
23
3.52
2.28
1.6
1.6
—
—
—
0
0
36
220
1.68
2.19
3.2
3.1
4.2
4.5
pmol/l
1.61
30
191
19
351
0.52
2.09
1.7
1.8
—
—
—
0
0
33
201
1.69
2.04
1.0
1.0
—
—
—
0
0
57
397
1.49
2.02
5.3
3.0
—
—
—
0
0
7
21
3.36
1.97
1.6
1.5
—
—
—
0
0
7
21
3.36
1.97
1.6
1.5
—
—
—
0
0
7
21
3.36
1.97
1.0
1.1
—
—
—
0
0
5
11
4.58
1.94
1.2
1.2
—
—
—
0
0
13
58
2.27
1.92
1.2
1.1
—
—
—
0
0
341
3114
1.28
1.90
4.8
3.8
15.0
14.8
pmol/l
0.75
318
2802
10
40
2.53
1.84
1.4
1.4
—
—
—
0
0
6
17
3.56
1.84
2.5
1.4
—
—
—
0
0
6
17
3.56
1.84
2.5
1.4
—
—
—
0
0
16
80
2.03
1.82
1.4
1.4
—
—
—
0
0
6
18
3.36
1.75
2.0
1.4
—
—
—
0
0
6
18
3.36
1.75
1.0
1.3
—
—
—
0
0
9
36
2.53
1.74
3.6
2.3
—
—
—
0
0
5
13
3.87
1.72
1.0
1.2
—
—
—
0
0
5
13
3.87
1.72
1.0
1.1
—
—
—
0
0
5
13
3.87
1.72
1.0
1.1
1323.8
1056.5
miu/ml
—
5
13
7
25
2.82
1.65
1.6
1.4
—
—
—
0
0
397
3724
1.28
1.62
5.6
4.6
1.9
2.2
mu/l
0.47
375
3376
18
99
1.85
1.59
1.4
1.6
3.8
5.1
iu/l
—
7
32
13
64
2.06
1.55
1.5
1.1
—
—
—
0
0
14
72
1.97
1.50
3.2
2.0
114.0
133.1
g/l
—
7
54
143
1208
1.25
1.48
3.2
3.0
6.7
7.4
mmol/l
1.13
124
1009
20
117
1.74
1.47
1.5
1.5
—
—
—
0
0
22
134
1.67
1.41
1.3
1.4
—
—
—
0
0
9
40
2.27
1.40
4.0
3.6
—
—
—
0
0
383
4038
0.80
1.38
4.9
4.3
1.4
1.5
mmol/l
4.12
360
3691
9
42
2.16
1.34
1.2
1.0
—
—
—
0
0
40
285
1.44
1.32
2.8
2.8
72.8
68.8
ml/min/173m2
0.13
12
121
387
4069
0.81
1.31
4.9
4.3
4.8
4.7
mmol/l
1.33
363
3746
368
3889
0.81
1.31
4.6
3.9
1.5
1.3
mmol/l
4.22
346
3530
6
24
2.52
1.30
2.5
1.4
—
—
—
0
0
6
24
2.52
1.30
2.5
1.4
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
25
2.42
1.24
1.2
1.2
—
—
—
0
0
7
30
2.35
1.12
2.1
1.3
1.0
1.0
g/l
—
7
30
58
458
1.30
1.05
2.5
4.3
3.0
41.8
ug/l
1.46
46
385
5
22
2.28
1.03
1.0
1.1
—
—
—
0
0
14
83
1.71
1.02
1.1
1.0
—
—
—
0
0
9
48
1.89
1.01
1.8
1.4
—
—
—
0
0
13
76
1.73
0.99
4.2
2.1
15.2
16.8
%
—
5
37
452
4375
1.26
0.99
25.4
9.1
31.2
25.6
u/l
7.33
445
4193
9
49
1.85
0.99
1.8
1.4
—
—
—
0
0
9
49
1.85
0.99
1.8
1.4
—
—
—
0
0
9
49
1.85
0.99
1.8
1.4
—
—
—
0
0
14
84
1.69
0.98
3.0
3.7
31.7
26.7
mg/l
—
8
52
398
4140
0.83
0.97
5.2
4.8
2.9
2.8
mmol/l
1.73
376
3788
9
50
1.81
0.97
1.8
1.4
—
—
—
0
0
9
50
1.81
0.97
1.8
1.4
—
—
—
0
0
437
4217
1.23
0.96
30.5
14.6
139.3
139.7
mmol/l
2.28
427
4078
13
77
1.71
0.96
1.1
1.2
—
—
—
0
0
6
30
2.01
0.87
1.3
1.2
—
—
—
0
0
437
4234
1.21
0.81
30.9
14.7
3.9
4.0
mmol/l
1.67
427
4089
135
1206
1.16
0.77
3.9
3.8
7.2
9.8
mg/mmol
0.45
85
740
16
108
1.50
0.74
9.8
2.8
3.9
3.9
mmol/l
0.00
16
102
403
3889
1.16
0.73
24.9
11.8
85.8
80.9
ml/min/173m2
3.69
359
3133
76
653
1.19
0.69
1.5
1.4
—
—
—
0
0
54
449
1.23
0.68
1.4
1.8
1.5
1.4
%
0.16
43
393
10
63
1.60
0.62
1.2
1.6
—
—
—
0
0
6
35
1.72
0.58
2.0
2.4
13.7
13.0
%
—
6
35
8
55
1.46
0.56
1.0
1.3
—
0.9
nmol/l
—
0
6
22
168
1.32
0.56
7.5
5.3
2.0
1.6
%
1.83
17
159
17
127
1.35
0.50
2.0
1.7
—
—
—
0
0
26
321
0.80
0.48
2.7
1.8
—
—
—
0
0
0
17
0.00
0.40
0.0
1.4
—
—
—
0
0
6
42
1.43
0.35
2.2
2.1
—
13.4
—
0
11
30
255
1.19
0.35
1.3
1.2
96.1
124.5
iu/ml
—
8
100
6
47
1.28
0.32
2.2
1.6
—
—
—
0
0
8
107
0.74
0.29
1.5
1.2
—
—
—
0
0
367
3745
0.93
0.29
34.7
13.7
39.2
39.9
%
0.70
255
2652
118
1111
1.08
0.29
4.7
4.9
3.9
2.9
ug/l
0.40
107
995
248
2401
1.06
0.27
3.1
2.8
—
—
—
0
0
383
3762
1.07
0.26
6.3
5.5
40.1
39.8
mmol/mol
0.22
364
3454
119
1129
1.07
0.24
1.6
1.6
1.6
1.4
mmol/l
1.94
102
938
5
40
1.25
0.22
1.2
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
9
111
0.81
0.20
1.1
1.5
—
—
—
0
0
86
907
0.94
0.19
3.6
4.3
22.4
21.8
%
0.18
43
431
393
3977
0.95
0.17
5.0
4.4
5.7
5.9
mmol/l
3.38
366
3604
5
68
0.73
0.17
1.0
1.5
—
—
—
0
0
33
360
0.91
0.16
2.5
1.9
—
—
—
0
0
55
519
1.07
0.14
4.9
4.2
30.1
31.8
%
0.65
42
331
51
483
1.06
0.12
9.1
6.4
—
—
—
0
0
13
115
1.13
0.10
1.8
1.4
—
—
—
0
0
69
664
1.05
0.10
2.7
2.9
0.7
0.8
ug/l
0.27
48
437
5
45
1.11
0.10
1.2
1.7
—
—
—
0
0
19
177
1.08
0.06
2.1
1.9
—
—
—
0
0
15
140
1.07
0.04
2.1
1.8
—
—
—
0
0
69
676
1.02
0.04
1.6
1.4
—
—
—
0
0
5
49
1.02
0.00
1.4
1.4
31.3
31.8
u/l
—
5
40
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
3.0
—
96.6
—
0
6
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
7
69
1.01
0.00
1.4
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
1.2
—
0
7
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
5
54
0.93
0.00
1.6
1.3
7.8
7.6
mmol/l
—
5
35
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint DERMATOPOLY_FG and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| DERMATOPOLY_FG | 2.299 [1.97, 2.68] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.13 |
During the follow-up period (1.1.1998 — 31.12.2019), 396 out of 1305 females with DERMATOPOLY_FG died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| DERMATOPOLY_FG | 2.482 [2.06, 3.0] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 296 out of 812 males with DERMATOPOLY_FG died.
Mortality risk
Mortality risk for people of age
years, who have DERMATOPOLY_FG.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.186% | 0.452% |
| 5 | 1.199% | 2.697% |
| 10 | 3.158% | 6.784% |
| 15 | 5.816% | 11.73% |
| 20 | 10.511% | 19.65% |
Relationships between endpoints
↥Index endpoint: DERMATOPOLY_FG – Dermatopolymyositis (FG)
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data